ADSB-FUB-187 explained

ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB₁ receptor with a binding affinity of K_i = 0.09 nM and an EC₅₀ of 1.09 nM.^[1] It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of K_i, it is not the most potent compound at producing a CB₁ mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC₅₀ values.^[2]

Legality

Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market synthetic cannabis products.^[3]

See also

• AB-FUBINACA
• ADB-FUBINACA
• ADB-5'F-BUTINACA
• ADB-5'Br-PINACA
• MDMB-5'Br-BUTINACA

Notes and References

1. Book: Banister SD, Connor M . New Psychoactive Substances . The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution . Handbook of Experimental Pharmacology . 252 . . 191–226 . 2018 . 30105473 . 10.1007/164_2018_144 . 978-3-030-10560-0 .
2. WO . 2009106982 . Indazole derivatives . Buchler IP, Hayes MJ, Hedge SG, Landis S, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KW . Pfizer Inc. . 3 September 2009 . . .
3. Web site: Cannabinoider föreslås bli klassade som hälsofarlig vara . https://web.archive.org/web/20150325081230/http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/ . 25 March 2015 . Folkhälsomyndigheten (The Swedish Public Health Agency) . Cannabinoids are proposed to be classified as hazardous to health . sv . 8 July 2015.